POLPHARMA BIOLOGICS S.A.
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Private
- Established
- 1935-01-01
- Employees
- 501
- Market Cap
- -
Clinical Trials
9
Active:3
Completed:3
Trial Phases
2 Phases
Phase 1:3
Phase 3:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 3
4 (57.1%)Phase 1
3 (42.9%)Efficacy, Safety and Immunogenicity of the Proposed Biosimilar Vedolizumab PB016 in Comparison With Entyvio®
Phase 3
Active, not recruiting
- Conditions
- Ulcerative Colitis
- Interventions
- Biological: Intravenous (IV) infusions
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Polpharma Biologics S.A.
- Target Recruit Count
- 750
- Registration Number
- NCT05771155
- Locations
- 🇬🇪
Todua Clinic LLC, Tbilisi, Georgia
Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®
Phase 3
Completed
- Conditions
- Relapsing-Remitting Multiple Sclerosis (RRMS)
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Polpharma Biologics S.A.
- Target Recruit Count
- 265
- Registration Number
- NCT04115488
- Locations
- 🇧🇾
Grodno Regional Clinical Hospital, Grodno, Belarus
🇧🇾Minsk City Clinical Hospital #5, Minsk, Belarus
🇧🇾Republican Research and Development Center for Neurology and Neurosurgery, Minsk, Belarus
News
No news found